Characterization of the H-kininogen-binding site on factor XI
Standard
Characterization of the H-kininogen-binding site on factor XI : a comparison of factor XI and plasma prekallikrein. / Renné, Thomas; Gailani, David; Meijers, Joost C M; Müller-Esterl, Werner.
In: J BIOL CHEM, Vol. 277, No. 7, 15.02.2002, p. 4892-9.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Characterization of the H-kininogen-binding site on factor XI
T2 - a comparison of factor XI and plasma prekallikrein
AU - Renné, Thomas
AU - Gailani, David
AU - Meijers, Joost C M
AU - Müller-Esterl, Werner
PY - 2002/2/15
Y1 - 2002/2/15
N2 - Factor XI (FXI), the zymogen of the blood coagulation protease FXIa, and the structurally homologous protein plasma prekallikrein circulate in plasma in noncovalent complexes with H-kininogen (HK). HK binds to the heavy chains of FXI and of prekallikrein. Each chain contains four apple domains (F1-F4 for FXI and P1-P4 for prekallikrein). Previous studies indicated that the HK-binding site on FXI is located in F1, whereas the major HK-binding site on prekallikrein is in P2. To determine the contribution of each FXI apple domain to HK-FXI complex formation, we examined binding of recombinant single apple domain-tissue plasminogen activator fusion proteins to HK. The order of affinity from highest to lowest is F2 F4 > F1 F3. Monoclonal antibodies against F2 are superior to F4 or F1 antibodies as inhibitors of HK binding to FXI. Antibody alphaP2, raised against prekallikrein, cross-reacts with FXI F2 and inhibits FXI-HK binding with an IC(50) of 8 nm. HK binding to a platelet-specific FXI variant lacking the N-terminal half of F2 is reduced > 5-fold compared with full-length FXI. A chimeric FXI molecule in which F2 is replaced by P2 is cleaved within P2 during activation by factor XIIa, resulting in greatly reduced HK binding capacity. In contrast, wild-type FXI is not cleaved within F2, and its binding capacity for HK is unaffected by factor XIIa. Our data show that HK binding to FXI involves multiple apple domains, with F2 being most important. The findings demonstrate a similarity in mechanism for FXI and prekallikrein binding to HK.
AB - Factor XI (FXI), the zymogen of the blood coagulation protease FXIa, and the structurally homologous protein plasma prekallikrein circulate in plasma in noncovalent complexes with H-kininogen (HK). HK binds to the heavy chains of FXI and of prekallikrein. Each chain contains four apple domains (F1-F4 for FXI and P1-P4 for prekallikrein). Previous studies indicated that the HK-binding site on FXI is located in F1, whereas the major HK-binding site on prekallikrein is in P2. To determine the contribution of each FXI apple domain to HK-FXI complex formation, we examined binding of recombinant single apple domain-tissue plasminogen activator fusion proteins to HK. The order of affinity from highest to lowest is F2 F4 > F1 F3. Monoclonal antibodies against F2 are superior to F4 or F1 antibodies as inhibitors of HK binding to FXI. Antibody alphaP2, raised against prekallikrein, cross-reacts with FXI F2 and inhibits FXI-HK binding with an IC(50) of 8 nm. HK binding to a platelet-specific FXI variant lacking the N-terminal half of F2 is reduced > 5-fold compared with full-length FXI. A chimeric FXI molecule in which F2 is replaced by P2 is cleaved within P2 during activation by factor XIIa, resulting in greatly reduced HK binding capacity. In contrast, wild-type FXI is not cleaved within F2, and its binding capacity for HK is unaffected by factor XIIa. Our data show that HK binding to FXI involves multiple apple domains, with F2 being most important. The findings demonstrate a similarity in mechanism for FXI and prekallikrein binding to HK.
KW - Alternative Splicing
KW - Animals
KW - Binding Sites
KW - Blotting, Western
KW - Cell Line
KW - Cricetinae
KW - Dose-Response Relationship, Drug
KW - Electrophoresis, Polyacrylamide Gel
KW - Enzyme-Linked Immunosorbent Assay
KW - Factor XI
KW - Humans
KW - Inhibitory Concentration 50
KW - Kininogen, High-Molecular-Weight
KW - Precipitin Tests
KW - Prekallikrein
KW - Protein Binding
KW - Protein Structure, Tertiary
KW - Recombinant Fusion Proteins
U2 - 10.1074/jbc.M105221200
DO - 10.1074/jbc.M105221200
M3 - SCORING: Journal article
C2 - 11733491
VL - 277
SP - 4892
EP - 4899
JO - J BIOL CHEM
JF - J BIOL CHEM
SN - 0021-9258
IS - 7
ER -